• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Lupin signs agreement with Natco for Fosrenol

      Posted AtEconomictimes.indiatimes.com

      MUMBAI: Lupin, one of India’s largest pharma companies, on Thursday said it has signed an agreement with mid sized firm Natco to market the generic version of Fosrenol(r) tablets, that are used to treat chronic kidney ailments. Although India is a key market for the product, the drug is reported to have totalled $108 million in sales in the US in December 2008.

      The agreement with Lupin will also help Natco fight a patent lawsuit that Fosrenol(r) innovator, Shire, a UK-based company, had filed recently, said a Natco spokesperson. Shire had filed the lawsuit in response to an abbreviated new drug application (ANDA) filing by Natco seeking US FDA approval to market and sell the generic versions of Shire’s 500 mg, 750 mg and 1g Fosrenol (r) tablets.

      Shares of Lupin were down marginally at Rs 652.50 in intra day trade on the BSE, while Natco Pharma surged 6.3% to Rs 55 on the BSE. Fosrenol is a drug used for hyperphosphatemia, a chronic kidney disease that leads to abnormally elevated levels of phosphate in the blood.

      Both Lupin and Natco say they are amongst one of the first to file for an ANDA which would lead to 180 days exclusivity that would allow only the two Indian firms to sell the generic versions.

      "The alliance creates synergies that will enable portfolio expansion and contribute to consolidating our presence in the US markets," said Lupin group president and executive director Nilesh Gupta. "Lupin's proven IP management capabilities, marketing reach and expertise coupled with Natco’s solid development and manufacturing abilities make for a great combination."

      According to Natco Pharma COO Rajeev Nannapaneni: "Our alliance brings together a strong philosophy of working together to maximize opportunities in an increasingly competitive generic business. We are very happy to be associated with Lupin, given their intellectual property management competencies and market strengths in the US."

      April 20, 2009


      Share this Article!

    Back to top^